CH7057288

Research use only, not for human use.

CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM 7.8 nM and 5.1 nM for TRKA TRKB and TRKC respectively.

CH7057288 is an effective and selective TRK inhibitor with an IC50 value of 1.1 nM 7.8 nM and 5.1 nM for TRKA TRKB and TRKC respectively.

CH7057288 induces regression of intracranial tumors and greatly improves event-free survival in an intracranial implantation model mimicking brain metastasis. CH7057288 can be a promising therapeutic agent for TRK fusion-positive cancer. TRK receptor tyrosine kinases are expressed as fusion proteins encoded by various fusion genes across a wide variety of cancer types, including lung and colorectal cancer.

——

——

Tyrosine Kinase

Trk Receptor

Trk

——

——

2095616-82-1

569.67

C32H31N3O5S

>98% (HPLC)

DMSO:34 mg/mL (59.68 mM)

Cc1cc(cc(n1)C#Cc1ccc2c3c(oc2c1)C(C)(C)c1cc(NS(C)(=O)=O)ccc1C3=O)C(=O)NC(C)(C)C

N-(tert-butyl)-2-((66-dimethyl-8-(methylsulfonamido)-11-oxo-611-dihydronaphtho[23-b]benzofuran-3-yl)ethynyl)-6-methylisonicotinamide

(-20℃)

With Ice Pack

≥ 2 years